+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Central Nervous System Drugs Market Research Reports

D2 Agonist - Pipeline Insight, 2025 - Product Thumbnail Image

D2 Agonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Muscarinic Acetylcholine Receptor M2 Antagonist - Pipeline Insight, 2025 - Product Thumbnail Image

Muscarinic Acetylcholine Receptor M2 Antagonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Ionotropic Glutamate Receptor Antagonists - Pipeline Insight, 2025 - Product Thumbnail Image

Ionotropic Glutamate Receptor Antagonists - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 100 Pages
  • Global
From
Acetylcholine Receptor (AChR) Antagonists - Pipeline Insight, 2025 - Product Thumbnail Image

Acetylcholine Receptor (AChR) Antagonists - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
GABAA Agonist - Pipeline Insight, 2025 - Product Thumbnail Image

GABAA Agonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 120 Pages
  • Global
From
GABA Receptor Agonists - Pipeline Insight, 2025 - Product Thumbnail Image

GABA Receptor Agonists - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 90 Pages
  • Global
From
Benzodiazepine Receptor Agonist - Pipeline Insight, 2025 - Product Thumbnail Image

Benzodiazepine Receptor Agonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 120 Pages
  • Global
From
Dopaminergic System Antagonist - Pipeline Insight, 2025 - Product Thumbnail Image

Dopaminergic System Antagonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 120 Pages
  • Global
From
Dyskinesia- Pipeline Insight, 2025 - Product Thumbnail Image

Dyskinesia- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
Chemotherapy Induced Peripheral Neuropathy- Pipeline Insight, 2025 - Product Thumbnail Image

Chemotherapy Induced Peripheral Neuropathy- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Chronic Spinal Cord Injury- Pipeline Insight, 2025 - Product Thumbnail Image

Chronic Spinal Cord Injury- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Adrenoleukodystrophy - Pipeline Insight, 2025 - Product Thumbnail Image

Adrenoleukodystrophy - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Refractory Epilepsy - Pipeline Insight, 2025 - Product Thumbnail Image

Refractory Epilepsy - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Tay-Sachs Disease- Pipeline Insight, 2025 - Product Thumbnail Image

Tay-Sachs Disease- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Sudden Sensorineural Hearing Loss (SSNHL) - Pipeline Insight, 2025 - Product Thumbnail Image

Sudden Sensorineural Hearing Loss (SSNHL) - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
From
From
Alzheimer's Disease (AD) - Epidemiology Forecast - 2034 - Product Thumbnail Image

Alzheimer's Disease (AD) - Epidemiology Forecast - 2034

  • Report
  • December 2024
  • 157 Pages
  • Global
From
Myotonic Dystrophy - Epidemiology Forecast - 2034 - Product Thumbnail Image

Myotonic Dystrophy - Epidemiology Forecast - 2034

  • Report
  • December 2024
  • 105 Pages
  • Global
From
Dementia with Lewy Bodies (DLB) - Epidemiology Forecast - 2034 - Product Thumbnail Image

Dementia with Lewy Bodies (DLB) - Epidemiology Forecast - 2034

  • Report
  • December 2024
  • 88 Pages
  • Global
From
Loading Indicator

The Central Nervous System Drugs market is a sector of the pharmaceutical industry that focuses on the development and production of drugs that target the central nervous system. These drugs are used to treat a variety of conditions, including neurological disorders, mental health issues, and pain management. The market is composed of a variety of companies, ranging from large multinationals to small start-ups. The Central Nervous System Drugs market is highly competitive, with companies competing to develop the most effective and safe treatments. Companies in the market are constantly researching and developing new drugs, as well as improving existing treatments. Many of these companies are also involved in clinical trials to test the safety and efficacy of their products. Some of the major companies in the Central Nervous System Drugs market include Pfizer, GlaxoSmithKline, Merck, Novartis, and Johnson & Johnson. These companies are involved in the development and production of a wide range of CNS drugs, including antidepressants, antipsychotics, and anticonvulsants. Show Less Read more